Judge accepts Paxil deal

Share this article:
An Illinois judge approved a $64-million class-action deal involving anti-depressant Paxil. The agreement, under which plaintiffs can get full refunds for their Paxil purchases, settles claims GlaxoSmithKline misled consumers by promoting the drug to children. Parties in the suit originally made the arrangement last November, contingent on a hearing to determine whether the settlement was fair and whether plaintiff’s attorneys were entitled to the $16 million settlement fee they requested. Last year the FDA issued warnings against use of Paxil in children after studies found the drug increased suicidal tendencies while having questionable effects on depression.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...